Barry A. Labinger
Chief Executive Officer bij Gilboa Therapeutics Ltd.
Profiel
Barry A.
Labinger currently works at Gilboa Therapeutics Ltd., as Chief Executive Officer from 2022.
Mr. Labinger also formerly worked at Checkmate Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2018 to 2021, Biothera Pharmaceutical, Inc., as President & Chief Executive Officer from 2015 to 2018, Bristol Myers Squibb Co., as Senior Director-Diabetes Marketing from 1997 to 2000, Anadys Pharmaceuticals, Inc., as Director in 2011, Biothera, Inc., as President, Chief Executive Director & Director, Immunex Corp., as SVP, VP-Marketing & GM-Commercial Operations from 2000 to 2002, 3M Co., as Divisional Vice President from 2002 to 2005, Human Genome Sciences, Inc., as Chief Commercial Officer & Executive VP from 2010 to 2012, and Emergent BioSolutions, Inc., as Executive VP & President-Biosciences Division from 2013 to 2016.
Mr. Labinger received his undergraduate degree from Northwestern University and Masters Business Admin degree from Kellogg School of Management.
Actieve functies van Barry A. Labinger
| Bedrijven | Functie | Begin |
|---|---|---|
Gilboa Therapeutics Ltd.
 Gilboa Therapeutics Ltd. BiotechnologyHealth Technology Gilboa Therapeutics Ltd. is a preclinical-stage biopharmaceutical company located in Israel. The Israeli company is focused on developing novel and high-impact, next-generation cancer immunotherapies that harness the power of a patient's own immune system to treat cancer, improve outcomes, and save lives. Gilboa's proprietary technology, solidt, is an engineered cell therapy that targets multiple different tumor types and is intended to be used in combination with a wide range of antigen-specific antibodies. The company is driven by a sense of urgency to discover, develop, and rapidly bring their game-changing new therapeutics to cancer patients in need, significantly improving outcomes and saving lives. | Chief Executive Officer | 01-05-2022 |
Eerdere bekende functies van Barry A. Labinger
| Bedrijven | Functie | Einde |
|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Chief Executive Officer | 27-10-2021 |
Biothera Pharmaceutical, Inc.
 Biothera Pharmaceutical, Inc. Medical/Nursing ServicesHealth Services Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN. | Chief Executive Officer | 01-12-2018 |
| EMERGENT BIOSOLUTIONS INC. | Corporate Officer/Principal | 04-01-2016 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Director of Finance/CFO | 23-03-2010 |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Director/Board Member | 23-11-2011 |
Opleiding van Barry A. Labinger
| Northwestern University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| 3M COMPANY | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | Commercial Services |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Biothera Pharmaceutical, Inc.
Biothera Pharmaceutical, Inc. Medical/Nursing ServicesHealth Services Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN. | Health Services |
Gilboa Therapeutics Ltd.
Gilboa Therapeutics Ltd. BiotechnologyHealth Technology Gilboa Therapeutics Ltd. is a preclinical-stage biopharmaceutical company located in Israel. The Israeli company is focused on developing novel and high-impact, next-generation cancer immunotherapies that harness the power of a patient's own immune system to treat cancer, improve outcomes, and save lives. Gilboa's proprietary technology, solidt, is an engineered cell therapy that targets multiple different tumor types and is intended to be used in combination with a wide range of antigen-specific antibodies. The company is driven by a sense of urgency to discover, develop, and rapidly bring their game-changing new therapeutics to cancer patients in need, significantly improving outcomes and saving lives. | Health Technology |
